Insiders Updates
CRISPR Therapeutics AG’s latest rating changes from various analysts
In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million
Menu
In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million
CRISPR Therapeutics AG’s recently made public that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
CRISPR Therapeutics AG’s filing revealed that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million on
In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million
In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million
CRISPR Therapeutics AG’s filing revealed that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million on
In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
CRISPR Therapeutics AG’s recently made public that its Director Treco Douglas A acquired Company’s shares for reported $1.14 million on